The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.
 
Elisa A. Rozeman
No Relationships to Disclose
 
Judith M. Versluis
No Relationships to Disclose
 
Karolina Sikorska
No Relationships to Disclose
 
Ruben Lacroix
No Relationships to Disclose
 
Lindsay G Grijpink-Ongering
No Relationships to Disclose
 
Birthe Heeres
No Relationships to Disclose
 
Bart A. Van De Wiel
No Relationships to Disclose
 
Petros Dimitriadis
No Relationships to Disclose
 
Ayşegül Sari
No Relationships to Disclose
 
Stijn Heijmink
No Relationships to Disclose
 
Pia Kvistborg
Consulting or Advisory Role - Personalis (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Daan van den Broek
No Relationships to Disclose
 
Annegien Broeks
No Relationships to Disclose
 
Jan Willem de Groot
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst); SERVIER (Inst)
 
Sofie Wilgenhof
No Relationships to Disclose
 
Marieke Anne Vollebergh
No Relationships to Disclose
 
Johannes V. Van Thienen
Consulting or Advisory Role - Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Roche
 
John B. A. G. Haanen
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celsius Therapeutics (Inst); Celsius Therapeutics (Inst); Celsius Therapeutics (Inst); Celsius Therapeutics (Inst); Gadeta (Inst); Gadeta (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Immunocore (Inst); Immunocore (Inst); Immunocore (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
 
Christian U. Blank
Stock and Other Ownership Interests - Forty Seven; Neon Therapeutics; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb